Photos provided by Johnson & Johnson
March 12, 2026
Johnson & Johnson announced today U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery.1 TECNIS PureSee IOL delivers clarity of vision for patients, with 97% of them reporting no very bothersome visual disturbances.1 TECNIS PureSee IOL will be available for patients in the U.S. later this year.
“Today marks an exciting milestone for people living with cataracts. The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs,” said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. “Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range and visual performance they expect from a Johnson & Johnson product.”
Cataracts naturally form as the eye ages, making everyday activities such as reading, driving and recognizing faces more difficult. Cataract surgery is one of the safest and most commonly performed procedures worldwide, offering patients the removal of a clouded natural lens and also the opportunity to enhance their vision.3 In a single procedure, TECNIS PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia,1 which occurs when your eyes gradually lose the ability to see objects clearly up close.4 Currently, an estimated 94 million people aged 50 years and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery.5
TECNIS PureSee IOL
TECNIS PureSee IOL is the first and only U.S. FDA‑approved EDOF IOL with no warning on loss of contrast sensitivity.1* Contrast sensitivity refers to a patient’s ability to distinguish an object from its background, an important part of visual quality, especially in low‑light or foggy conditions. Aspheric monofocal IOLs are widely considered the benchmark for preserving contrast sensitivity, and by maintaining contrast sensitivity comparable to an aspheric monofocal IOL, TECNIS PureSee IOL helps patients experience the visual clarity and confidence they expect, while also benefiting from an extended range of vision.1
TECNIS PureSee IOL is built on the industry‑leading TECNIS platform, combining advanced optics with proprietary material. It mitigates the effects of presbyopia by providing extended depth of focus, enabling excellent distance and intermediate vision, with some near vision.1** TECNIS PureSee IOL reduces patients’ reliance on glasses following surgery, with 97% of patients reporting no very bothersome visual disturbances.1,2
TECNIS PureSee IOL expands Johnson & Johnson’s surgical vision portfolio, which is backed by 25 years of innovation in intraocular lens technology. Each year, millions of patients worldwide receive TECNIS lenses as part of their cataract surgery.⁶ The TECNIS portfolio includes TECNIS PureSee IOL, a purely refractive EDOF IOL;1 TECNIS Odyssey IOL, a Full Visual Range (FVR) IOL;⁷ and TECNIS Eyhance IOL, the first monofocal IOL designed to slightly extend depth of focus.⁸
For more patient information and tools, click here.
Find indications and important safety information here.
References
*In clinical evaluation, TECNIS PureSee IOL demonstrated contrast sensitivity comparable to an aspheric monofocal intraocular lens, with no clinically meaningful differences (≤0.3 log units) versus aspheric monofocal controls across pupil sizes, while maintaining distance visual acuity and low levels of visual symptoms.
**TECNIS PureSee IOL achieved a 1.5-line difference in mean monocular distance-corrected near VA at 6 months compared to TECNIS 1-Piece.
1. 2026REF4592 TECNIS PureSee IOL with TECNIS SIMPLICITY Delivery System, Model DEN00V. Directions for Use, current revision. Z312075E, Rev B.
2. DOF2023CT4043 Clinical Investigation. Patient Satisfaction Outcomes. July 18, 2023.
3. Chen X, Xu J, Chen X, Yao K. Cataract: Advances in surgery and whether surgery remains the only treatment in future. 2021.
4. American Academy of Ophthalmology. What Is Presbyopia? https://www.aao.org/eye-health/diseases/what-is-presbyopia
5. World Health Organization. Report of the 2030 targets on effective coverage of eye care. 2025.
6. 2024REF6182. 2024 Market Scope IOL Market Report.
7. TECNIS Odyssey IOL with TECNIS SIMPLICITY Delivery System, Model DRN00V. Directions for Use, current revision.
8. TECNIS Eyhance IOL with TECNIS SIMPLICITY Delivery System, US Directions for Use, current revision.
